Targeted Delivery of Doxorubicin to HER2 Positive Tumor Models

International Journal of Nanomedicine - New Zealand
doi 10.2147/ijn.s210731
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Informa UK Limited

Related search

Biocompatible and Biodegradable Fibrinogen Microspheres for Tumor-Targeted Doxorubicin Delivery

International Journal of Nanomedicine
Organic ChemistryBiophysicsBiomaterialsPharmaceutical ScienceMedicineBioengineeringDrug DiscoveryNanoscienceNanotechnology
2015English

Synthesis and Evaluation of Doxorubicin-Loaded Gold Nanoparticles for Tumor-Targeted Drug Delivery

English

Targeted Therapy for HER2 Positive Breast Cancer

Journal of Hematology and Oncology
Cancer ResearchOncologyHematologyMolecular Biology
2013English

Theranostic pH-sensitive Nanoparticles for Highly Efficient Targeted Delivery of Doxorubicin for Breast Tumor Treatment

International Journal of Nanomedicine
Organic ChemistryBiophysicsBiomaterialsPharmaceutical ScienceMedicineBioengineeringDrug DiscoveryNanoscienceNanotechnology
2018English

A Biparatopic HER2-Targeting Antibody-Drug Conjugate Induces Tumor Regression in Primary Models Refractory to or Ineligible for HER2-Targeted Therapy

Cancer Cell
Cancer ResearchOncologyCell Biology
2016English

A Biparatopic HER2-Targeting Antibody-Drug Conjugate Induces Tumor Regression in Primary Models Refractory to or Ineligible for HER2-Targeted Therapy

Cancer Cell
Cancer ResearchOncologyCell Biology
2019English

Selection of a Novel CD19 Aptamer for Targeted Delivery of Doxorubicin to Lymphoma Cells

Oncotarget
Oncology
2018English

Safety and Pharmacokinetics of MM-302, a HER2-targeted Antibody–liposomal Doxorubicin Conjugate, in Patients With Advanced HER2-positive Breast Cancer: A Phase 1 Dose-Escalation Study

British Journal of Cancer
Cancer ResearchOncology
2018English

Tumor-Targeted Drug Delivery With Aptamers

Current Medicinal Chemistry
Organic ChemistryBiochemistryDrug DiscoveryMolecular MedicinePharmacology
2011English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy